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Background: High-grade gliomas are one of the most invasive and therapy-resistant cancers. We have recently
shown that noncanonical NF-κB/RelB signaling is a potent driver of tumorigenesis and invasion in the aggressive,
mesenchymal subtype of glioma. However, the relevant signals that induce activation of noncanonical NF-κB signaling
in glioma and its function relative to the canonical NF-κB pathway remain elusive.
Methods: The ability of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to regulate NF-κB signaling
and promote tumor progression was investigated in both established and primary high-grade glioma tumor lines using
a three-dimensional (3-D) collagen invasion assay. The roles of specific NF-κB proteins in regulating glioma cell invasion
and expression of Matrix Metalloproteinase 9 (MMP9) in response to TWEAK were evaluated using shRNA-mediated
loss-of-function studies. The ability of NF-κB-inducing kinase (NIK) to promote glioma growth in vivo was investigated
using an orthotopic xenograft mouse model.
Results: In glioma cells that display elevated noncanonical NF-κB signaling, loss of RelB attenuates invasion without
affecting RelA expression or phosphorylation and RelB is sufficient to promote invasion in the absence of RelA. The
cytokine TWEAK preferentially activates the noncanonical NF-κB pathway through induction of p100 processing to p52
and nuclear accumulation of both RelB and p52 without activating the canonical NF-κB pathway. Moreover, TWEAK,
but not TNFα, significantly increases NIK mRNA levels. TWEAK also promotes noncanonical NFκB-dependent MMP9
expression and glioma cell invasion. Finally, expression of NIK is sufficient to increase gliomagenesis in vivo.
Conclusions: Our data establish a key role for NIK and noncanonical NF-κB in mediating TWEAK-induced,
MMP-dependent glioma cell invasion. The findings also demonstrate that TWEAK induces noncanonical NF-κB
signaling and signal-specific regulation of NIK mRNA expression. Together, these studies reveal the important
role of noncanonical NF-κB signaling in regulating glioma invasiveness and highlight the therapeutic potential
of targeting activation of NIK in this deadly disease.
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The aggressive, infiltrative growth of gliomas renders
them highly refractory to surgery, radiation and chemo-
therapy. Thus, understanding the biochemical and mo-
lecular pathways that control glioma cell invasion is
critical for identifying more effective therapeutic targets.
Aberrant activation of the canonical NF-κB pathway is
well documented in a variety of malignancies [1,2] and
plays important roles in regulating glioma invasion and
tumor progression [3-5]. However, specific roles for the
noncanonical NF-κB pathway in tumor pathogenesis,
particularly in solid tumors of the central nervous
system (CNS), are poorly understood.
NF-κB proteins are evolutionarily conserved tran-
scription factors that play central roles as coordinators
of key biological processes, including immunity, inflam-
mation, cell death and survival. The five mammalian
family members RelA (p65), RelB, c-Rel, NFKB1 (p105/
p50), and NFKB2 (p100/p52) share an evolutionarily con-
served Rel homology domain that mediates DNA binding
and dimerization with other NF-κB subunits. NF-κB
complexes are held in the cytoplasm in an inactive state,
bound to members of the NF-κB inhibitor (IκB) family,
which includes IκBα. In response to specific extracellu-
lar signals such as the cytokine tumor necrosis factor-α
(TNFα), activation of canonical NF-κB signaling is triggered
by signal-induced phosphorylation and degradation of IκBα,
followed by nuclear translocation of the active, liberated
RelA-p50 complexes. IκBα phosphorylation-induced degrad-
ation and activation of the canonical NF-κB pathway is
dependent on IκB kinase-β (IKKβ).
Noncanonical NF-κB signaling is mediated by RelB-p52
heterodimers whose activation is dependent on NF-κB-
inducing kinase (NIK). NIK, a mitogen-activated protein
kinase kinase kinase (MAP3K14), is regulated primarily
through protein stabilization [6]. In unstimulated cells,
NIK interacts with TNF receptor associated factor-3
(TRAF3) in a multi-subunit E3 ubiquitin ligase complex
which leads to NIK polyubiquitination and proteasomal
degradation [7]. Consequently, NIK protein levels are
maintained at low levels. A critical step in activation of
noncanonical NF-κB signaling is the ubiquitination-
mediated proteasomal degradation of TRAF3, which
stabilizes NIK protein, leading to IKKα activation and
phosphorylation of p100, an inhibitory IκB-like protein
that retains RelB in the cytoplasm. Phosphorylation of
p100 leads to its proteolytic processing to form p52,
culminating in nuclear translocation of transcriptionally
active RelB-p52 heterodimers [8,9]. Notably, unlike other
NF-κB proteins, RelB is inherently unstable and its protein
levels are stabilized by interaction with p100/p52 in the
cytoplasm [10] and DNA binding in the nucleus [11].
The noncanonical NF-κB pathway can be specifically
activated by signals such as B-cell-activating factor receptor(BAFFR) [6]. Some signals, such as TNF-like weak in-
ducer of apoptosis (TWEAK) have been shown to regu-
late both the canonical and noncanonical NF-κB
pathways for sustained NF-κB activation [12]. TWEAK
and its receptor, fibroblast growth factor-inducible pro-
tein 14 (Fn14), have recently been implicated in tumor
cell pathogenesis [13,14] and upregulation of MMP9
[15], which is generally associated with poor disease
prognosis due to its ability to promote tumor growth,
migration, invasion, and metastasis [16]. However, the
functional outcomes of TWEAK signaling in glioma
with regard to specific downstream NF-κB signaling
events are not clear. We have previously demonstrated
that the noncanonical NF-κB protein, RelB, is highly
expressed in a subset of aggressive, mesenchymal gli-
oma, where it is a potent driver of oncogenesis and a
predictor of survival in human patients [17]. In this
study, we investigate the effects of TWEAK on nonca-
nonical NF-κB/RelB signaling, MMP9 expression and
glioma invasion.
Results
The invasive potential of glioma tumor lines positively
correlates with RelB expression
Because aggressive invasion of high-grade gliomas into
normal health tissue is a significant barrier to treatment,
we sought to further evaluate the relationship between
NF-κB signaling pathways and glioma cell invasion. First,
we analyzed the invasive potential of both established
high-grade glioma tumor lines (U87 & U373) and pri-
mary brain tumor-derived lines (BT25, BT114, BT116,
BT132) using a three-dimmensional (3-D) collagen matrix
assay [18]. Compared with two-dimensional (2-D) assays,
modeling tumor cell invasion in 3-D collagen matrices bet-
ter reflects both the in vivo cell-cell and cell-extracellular
matrix interactions within a tumor [19], as well as the
significantly elevated levels of collagen in the adult
brain tumor microenvironment [20]. Analysis of side-
view images of cells invading the collagen matrix and
quantification of invading cells demonstrated that BT25,
BT116, and U87 cells were the most invasive tumor lines,
while BT132, BT114 and U373 were significantly less
invasive (Figure 1A). Quantification of invasion density
confirmed these observations (Figure 1B).
Next, we analyzed expression of canonical and nonca-
nonical NF-κB proteins in the different glioma tumor
lines. Western blot analysis demonstrated that, com-
pared with BT25 and BT114 cells, BT116, BT132, U87
and U373 cells exhibited higher levels of phosphorylated
RelA at serine 536 (RelA-P536), an marker of enhanced
NF-κB transcriptional activation potential [21,22], while
total RelA levels were comparable in all cell lines
(Figure 1C). We noted that neither total RelA, nor RelA-
P536 levels, correlated with invasiveness. For example,
Figure 1 Glioma cell invasion correlates positively with RelB expression. Equal numbers of glioma cells from indicated cell lines were
seeded on 3-D collagen matrices and allowed to invade for 48 h, fixed with 3% glutaraldehyde, and stained with 0.1% toluidine blue. (A) Side-view
light microscopy images were taken from thin slices of the collagen matrices at 10x magnification. White arrowheads indicate cell monolayer. Scale
bars = 100 μm. (B) Quantification of invasion density for cell lines in Figure 1A. Data represent average numbers of invading cells per 1-mm2 field
(n = 3 wells) ± S.E.M. (C) Western blot of whole-cell lysates from glioma lines using the indicated antibodies.
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well as low-invasive BT114 cells. Likewise, high RelA-
P536 expression was observed in both high-invasive
BT116 and low-invasive BT132 (see Figure 1A, B). In
contrast to RelA, RelB protein levels were more varied
in the different glioma lines, and high RelB-expressing
cells (U87, BT25, and BT116) invaded much more effi-
ciently than low RelB-expressing cells (BT132, BT114
and U373). These results demonstrate that levels of
RelB, but not RelA or RelA-P536, strongly correlate with
the invasive potential of glioma cells.RelB poteniates glioma invasion independently of RelA
We have previously reported that loss of RelB in gli-
oma significantly reduces the number and depth of
invading tumor cells [17]. To further characterize
and compare the roles of RelA and RelB in invasion,
we used lentivirally-delivered shRNA to inhbit ex-
pression of these proteins in the highly invasive
BT25 and U87 cells (Figure 2A). Side-view images of
3-D collagen invasion matrices and quantification of
invading cells demonstrated that loss of either RelA
or RelB each resulted in a significant decrease of
Figure 2 (See legend on next page.)
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Figure 2 RelB poteniates glioma invasion independently of RelA. (A) Western blot of whole-cell lysates from NSC-cultured BT25 and U87
cells transduced with lentiviral vectors expressing shRNA targeting RelA (shRelA), RelB (shRelB), or a scrambled control (shCon). (B) Representative
images of invading shRNA-transduced glioma cells at 48 h. White arrowheads indicate monolayer. Scale bars = 100 μm. (C) Quantification of invasion
density at 48 h for BT25 and U87 knockdown cell lines. Data represent average numbers of invading cells per 1-mm2 field (n = 3 wells) ± S.E.M.
***p < 0.001 relative to shCon using One-way ANOVA with Tukey’s H.S.D. post-test. (D) Western blot of whole-cell lysates from U87 shRelA cells
transduced with lentiviral vectors containing RFP cDNA (+Vector) or RelB cDNA (+RelB). (E) Quantification of invasion density at 48 h for U87
shRelA cells in Figure 2D. ***p < 0.001 relative to shCon using One-way ANOVA with Tukey’s H.S.D. post-test.
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itional file 1: Figure S1A, B). In shRelA cells, a sig-
nificant loss of RelB was observed (Figure 2A),
consistent with the known ability of RelA to regulate
expression of RelB [23]. In contrast, RelA protein
levels were not significantly affected in shRelB cells
(Figure 2A), demonstrating that the diminished
invasive potential was not due to loss of signaling
through the canonical, RelA-dependent, NF-κB
pathway.
Next, we tested whether ectopic expression of RelB
could restore the invasive potential of RelA knockdown
cells. U87 shRelA cells were transduced with lentivirus
to express either a control vector or RelB. We observed
that ectopic expression of RelB in the RelA knockdown
cells was approximately 5-fold higher than endogenous
RelB expression in shControl cells (Figure 2D and
Additional file 1: Figure S1C). Notably, overexpression
of RelB did not affect shRNA-mediated knockdown of
RelA and also did not alter the levels of either total or
phosphorylated RelA (Figure 2D). RelB was nevertheless
able to restore the loss of invasion observed in RelA
knockdown cells (Figure 2E). These results demonstrate
that in glioma cells with attenuated levels of RelA protein,
RelB can rescue invasion without increasing the expres-
sion or activity of RelA and canonical NF-κB signaling.
TWEAK promotes glioma cell invasion and predominantly
activates noncanonical NF-κB signaling
TWEAK has been reported to be an activator of both
canonical and noncanonical NF-κB pathways [12,24,25].
However, very high concentrations of TWEAK (100 ng/
ml) are required for activation of RelA [24]. We ob-
served that treatment with a low, physiological concen-
tration of TWEAK (10 ng/ml) was sufficient to increase
glioma invasion in the 3-D collagen matrices (Figure 3A).
Thus, we next examined the effect of TWEAK on NF-
κB signaling. Glioma cells were treated with TWEAK
(10 ng/ml) and western blot analysis was performed with
cytoplasmic and nuclear protein lysates. We observed
that TWEAK robustly induced noncanonical NF-κB
activity, as evidenced by increased p100 processing to
p52, as well as nuclear accumulation of both RelB and
p52 (Figure 3B). Increased nuclear accumulation of RelB
was observed as early as 15 minutes after treatment withTWEAK and reached peak levels at 4 hours, with a
concurrent increase in p100 processing and nuclear p52
and sustained levels of both proteins after 48 hours
(Figure 3B). Notably, nuclear translocation of RelA,
RelA-P536, p105, p50, or c-Rel was not induced by
TWEAK stimulation (Figure 3B and Additional file 1:
Figure S2A). Moreover, no degradation of IκBα was
observed in response to TWEAK (Figure 3B). In con-
trast, treatment with TNFα, a potent inducer of canonical
NF-κB activity, led to rapid degradation of IκBα, and phos-
phorylation and nuclear translocation of RelA (Figure 3C),
demonstrating that these cells have fully functional canon-
ical NF-κB signaling. TNFα also induced RelB nuclear
accumulation and p100 processing, albeit more transi-
ently compared with TWEAK treatment (Figure 3C). As
with TWEAK, TNFα induced RelB nuclear localization
starting at 15 minutes, reaching maximal levels at 4 hours.
However, levels of nuclear RelB returned to basal by 24–
48 hours (Figure 3C). Similar results were observed in
TNFα- and TWEAK-treated BT25 and U87 cells (data not
shown). Finally, consistent with predominant activation
of the noncanonical NF-κB pathway by TWEAK, we
observed a robust increase in NIK mRNA levels as early
as one hour after TWEAK treatment. TNFα, on the
other hand, did not significantly alter NIK expression
(Figure 3D). Induction of elevated NIK mRNA syn-
thesis at 4 hours post-TWEAK also correlated with
increased protein levels (Additional file 1: Figure S2B).
Together, these data provide strong evidence supporting
the ability of TWEAK to predominantly promote activa-
tion of the noncanonical NF-κB pathway in glioma.
TWEAK-dependent regulation of MMP9 expression is
mediated by the noncanonical NF-κB pathway
Matrix Metalloproteinases (MMPs) plays key roles in
many aspects of cancer pathogenesis, including regula-
tion of extracellular matrix remodeling during invasion
[16]. To investigate the role of MMPs in glioma cells in-
vasion, we tested the effects of a pan MMP inhibitor,
GM6001, in our 3-D invasion assays. We observed that
GM6001 blocked invasiveness of untreated cells in a
dose-dependent manner, with almost complete inhbition
of invasion with 1μM (Figure 4A, Additional file 1:
Figure S3A). The ability of TWEAK to promote invasion
was also proportionately reduced with GM6001 treatment
Figure 3 (See legend on next page.)
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Figure 3 TWEAK induces invasion, NIK mRNA expression, and noncanonical NF-κB nuclear translocation. (A) Quantification of BT116
invasion density at 48 h with or without 10 ng/ml TWEAK in the collagen matrix. Data represent average numbers of invading cells per 1-mm2
field (n = 3 wells) ± S.E.M. *p < 0.05 relative to vehicle control using unpaired Student’s t-test. (B)Western blot analysis of proteins from cytoplasmic
and nuclear fractions of BT116 cells stimulated with 10 ng/ml TWEAK for the indicated times using the indicated antibodies. (C) Western blot analysis
of cytoplasmic and nuclear fractions as in Figure 3B post-stimulation with 10 ng/ml TNFα for the indicated times. (D) qRT-PCR analysis of NIK mRNA
expression from BT116 cells. mRNA was collected at indicated time points after stimulation with TWEAK (10 ng/ml) or TNFα (10 ng/ml). Data represent
average mRNA expression relative to RPLP0 mRNA (n = 3 replicates) ± S.D.
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sion of MMPs, we performed qRT-PCR on BT116 glioma
cells treated with TWEAK (10 ng/ml) for 24 hours. Results
from these experiments demonstrate that TWEAK
robustly induced expression of MMP9 and negligibly
affected expression of MMP2 and MMP14 (Figure 4B).
Increased MMP9 expression was first discernable at
4 hours and peaking at 24–48 hours after TWEAK
stimulation, concurrent with induction of RelB and p52
nuclear localization (see Figure 3B). TNFα also increased
expression of MMP9 with more rapid kinetics but over-
all lower levels of induction compared to TWEAK
(Figure 4B).
Given these findings, we surmised that the lower effi-
cacy of GM6001 towards MMP9 activity (see Methods)
might account for its inability to attenuate TWEAK-
induced invasion. Therfore, to test the role of MMP9 in
TWEAK-induced invasion we performed the 3-D inva-
sion assay in the presence of a selective MMP9 inhibitor.
MMP9 Inhibitor I did not have a significant effect on
untreated U87 cells, however, the ability of TWEAK to
promote invasion was significantly attenuated (Additional
file 1: Figure S3B). Similar results were observed with
BT114 and BT116 cells (data not shown).
To determine whether noncanonical NF-κB activity is
required for TWEAK-induced MMP9 expression, we
transduced BT25, BT116, and U87 cells with shRNAs
targeting NFKB2 (p100) or a scrambled shRNA. Western
blot analysis demonstrated that loss of NFKB2 resulted in
a decrease in p100 protein levels and TWEAK-dependent
processing to p52 (Figure 4C). TWEAK induction of RelB
protein was also attenuated in NFKB2 knockdown cells
(Figure 4C). qRT-PCR analyses demonstrated that
although basal MMP9 mRNA levels were comparable
between shNFKB2 and shControl lines, the ability of
TWEAK to induce MMP9 expression was significantly
impaired in NFKB2 knockdown cells (Figure 4D). These
results demonstrate that TWEAK-mediated induction
of NIK and noncanonical NF-κB pathway are critical
for increasing expression of MMP9 and glioma cell
invasion.
Expression of NIK promotes gliomagenesis in vivo
Our data thus far demonstrate that a low concentration of
TWEAK promotes invasion and predominantly activatesnoncanonical NF-κB signaling in glioma tumor lines with
high RelB expression. Notably, we observed that similar to
BT116 cells, TWEAK was also able to promote invasion
in BT114 glioma cells, which are minimally invasive and
express low levels of RelB (Figure 5A; also see Figure 1).
TWEAK also significantly increased levels of NIK mRNA
in these cells (Figure 5B). Therefore, we investigated
whether NIK could potentiate noncanonical NF-κB signal-
ing and enhance gliomagenesis in vivo using an orthotopic
mouse xenograft model. Ectopic expression of NIK in
BT114 cells increased p100 processing to p52 compared
with BT114 cells expressing vector control, indicating that
the ectopically expressed NIK was functional (Figure 5C).
RelA-P536, IκBα, p50, and c-Rel levels were unaffected
by NIK overexpression, indicating that NIK did not
significantly affect the canonical NF-κB pathway (Additional
file 1: Figure S4). BT114-control and BT114-NIK cells
were fluorescently labeled and injected into the right
cortex of CD-1 nude mice. 3-D tomographic reconstruc-
tion of fluorescent images taken in vivo revealed that
BT114-NIK cells formed larger and more dispersed
tumors compared with BT114-control cells (Figure 5D).
Quantification of tumor volume demonstrated that
BT114-NIK cells formed significantly larger tumors
(Figure 5E). Finally, ex-vivo images taken 58 days after
intracranial injection confirmed that BT114-NIK cells
formed significantly larger tumors compared with
BT114-control (Figure 5E-F). Taken together, these
data reveal a key role for NIK and noncanonical NF-κB
signaling in glioma pathogenesis.
Discussion
Aberrant activation of the canonical NF-κB pathway has
been correlated with the promotion of brain cancer cell
survival and invasion. However, roles for the noncanoni-
cal NF-κB pathway in CNS pathologies are less clear.
RelB expression was previously described to be elevated
in the aggressive mesenchymal glioma subtype [26] and
we have recently identified a functional role for RelB
as a key driver of mesenchymal gene expression and
tumorigenesis [17]. A critical feature of the noncanonical
NF-κB signaling pathway is its dependence on the
regulation of NIK protein stability through proteasome-
dependent degradation [7]. We show that a low concen-
tration of TWEAK (10 ng/ml) preferentially and potently
Figure 4 (See legend on next page.)
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Figure 4 MMPs are required for glioma invasion and TWEAK-induced MMP9 expression is p52-dependent. (A) Quantification of invasion
density at 48 h for BT116 cells with or without 10 ng/ml TWEAK in the collagen matrix. Cells were treated during the 48 h invasion assay with
broad-spectrum MMP inhibitor GM6001 at indicated concentrations. Data represent average numbers of invading cells per 1-mm2 field (n = 3 wells) ±
S.E.M. **p < 0.01 ***p < 0.001 between indicated groups using unpaired Student’s t-test. (B) qRT-PCR analysis of MMP mRNA expression in cultured
BT116 cells. mRNA was collected at indicated time points after stimulation with TWEAK (10 ng/ml) or TNFα (10 ng/ml). Data represent average mRNA
expression relative to GAPDH mRNA and normalized to untreated cells at t = 0 (n = 3 replicates) ± S.D. (C) Western blot of whole-cell lysates from
cultured BT25, BT116, and U87 cells transduced with shRNA targeting p100/p52 (NFKB2) or a scrambled control (Control). Lysates were collected at
48 h after stimulation with 10 ng/ml TWEAK or vehicle control. White arrowhead indicates p52 band. Black arrowhead indicates non-specific band. (D)
qRT-PCR analysis of MMP9 mRNA expression from cell lines in Figure 4C. mRNA was collected at 48 h after stimulation with 10 ng/ml TWEAK or
vehicle control. Data represent average MMP9 mRNA expression relative to RPLP0 mRNA and normalized to untreated control (n = 3 replicates)
± S.D. ***p < 0.001 between indicated groups determined by unpaired Student’s t-test for each cell line.
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evidenced by induction of p100 processing to p52, and
nuclear accumulation of p52 and RelB (Figure 3). At
this concentration, TWEAK failed to induce significant
IκBα degradation and nuclear translocation of RelA (see
Figure 3B), suggesting minimal TWEAK-induced acti-
vation of the canonical NF-κB pathway in glioma cells.
Moreover, since a low concentration of TWEAK are
sufficent to promote noncanonical NF-κB-mediated cell
invasion, this pathway may be extremely important for
initiating early, aggressive tumor dissemination.
Interestingly, we observed that TWEAK can promote
noncanonical NF-κB signaling at the pre-translational
level, as evidenced by accumulation of NIK mRNA in
response to treatment with TWEAK. This induction of
NIK mRNA was specific for TWEAK since TNFα, a
potent inducer of the canonical NF-κB pathway, failed to
increase NIK expression (see Figure 3D). Pre-translational
regulation of NIK expression by TWEAK may be import-
ant for sustained activation of the noncanonical NF-κB
pathway during the invasion process. TWEAK is synthe-
sized in response to cellular injury and inflammation in
tumor cells, as well as many cell types of the CNS, includ-
ing neurons, microglia, and endothelial cells [27]. There-
fore, TWEAK may function in both an autocrine and
paracrine manner to robustly induce NIK expression, acti-
vate noncanonical NF-κB signaling and MMP expression,
thereby promoting tumor cell invasion. Overall, these data
provide compelling evidence that the pathological, pro-
invasive effects of TWEAK are preferentially mediated by
noncanonical NF-κB signaling.
Recently, noncanonical NF-κB signaling was shown to
promote glioma invasion in response to non-toxic doses
of BV-6, a potential chemotherapeutic agent that pro-
motes cancer cell death through antagonism of cellular
Inhibitors of Apoptosis proteins (c-IAPs) [28]. Our data
demonstrate that both basal, constitutive noncanonical
NF-κB activity, as well as induction of noncanonical NF-
κB signaling by an endogenous cytokine, TWEAK, play
critical roles in promoting glioma invasion. These find-
ings demonstrate that noncanonical NF-κB signaling notonly mediates therapy resistance, but also is important in
normal tumor brain pathogenesis.
Lastly, it was recently reported that IKK-dependent,
canonical NF-κB signaling suppresses NIK activity and
noncanonical NF-κB signaling [29]. In the context of
those findings, our data suggest that inhibition of ca-
nonical NF-κB pathway might result in increased con-
stitutive noncanonical NF-κB activity, therey promoting
tumor cell invasion and pathogenesis. Notably, the abil-
ity of TWEAK to induce NIK expression and promote
invasion is not only observed in glioma cells expressing
high levels of RelB, but also in glioma cells with low
levels of endogenous RelB expression (Figure 5). Altogether,
these data suggest that blocking TWEAK signaling and
noncanonical NF-κB activation, alone or in combination
with inhibition of canonical NF-κB signaling, will be
more efficacious for attenuation of tumor cell invasion
and, therefore, have therapeutic value in a broad range
of glioma subtypes.
Conclusion
Here, we establish a key role for noncanonical NF-κB
signaling in glioma that is independent of the canon-
ical NF-κB pathway. Specifically, we demonstrate that
RelB promotes glioma invasion in the absence of RelA,
and that TWEAK preferentially regulates noncanonical
NF-κB signaling in glioma through a novel, signal-
specific induction of NIK expression. Morevoer, NIK
is sufficient to promote brain tumor growth in vivo. To
date, therapeutic strategies targeting NF-κB have mostly
focused almost exclusively on inhibition of the canonical
NF-κB pathway [30]. Our findings provide a compelling
rationale for considering TWEAK/Fn14 and NIK inhib-
ition as therapeutic strategies for aggressive glioma, as well
as other highly invasive cancers.
Methods
Cell culture & reagents
BT lines from glioma patients (BT25, BT114, BT116,
BT132) were obtained as described previously [31].
293 T, U87-MG, and U373 cells were purchased from
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Figure 5 NIK mRNA is up-regulated by TWEAK and NIK protein overexpression promotes tumorigenesis. (A) Quantification of BT114
invasion density at 48 h with or without 10 ng/ml TWEAK in the collagen matrix. Data represent average numbers of invading cells per 1-mm2
field (n = 3 wells) ± S.E.M. ***p < 0.001 relative to vehicle control using unpaired Student’s t-test. (B) qRT-PCR analysis of NIK mRNA expression
from BT114 cells. mRNA was collected at 48 h after stimulation with 10 ng/ml TWEAK or vehicle control. Data represent average NIK mRNA
expression relative to RPLP0 mRNA and normalized to untreated control (n = 3 replicates) ± S.D. ***p < 0.001 relative to vehicle control using
unpaired Student’s t-test. (C) Western blot analysis of BT114 glioma cells transduced with lentivirus containing NIK cDNA or luciferase cDNA
(Con) using the indicated antibodies. (D) Representative IVIS images of 3-D rendering of tumors derived from DiD-stained intracranial-injected
BT114-control (n = 7 mice) or BT114-NIK (n = 9 mice) cells at 14 and 24 days post-injection (n = 3 mice per group). Numbers indicate scale of
Signal Intensity for each image. (E) Quantification of BT114 brain tumors in Figure 5D at 30 days. Data represent average tumor volume ± S.E.M.
*p < 0.05 relative to BT114 control using unpaired Student’s t-test. (F) Representative IVIS ex-vivo images of DiD-stained BT114 brain tumors in
Figure 5D at 58 days post-injection.
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10%FBS (1X Glutamax, 1X Pen/Strep) or Neural Stem
Cell (NSC) medium (DMEM/F12, 1X B-27 Supplement
minus Vitamin A, 1X Glutamax, 50 ng/ml EGF, 50 ng/ml bFGF, 1X Pen/Strep). All cell culture reagents were
from Life Technologies (Grand Island, NY). rhTNFα was
obtained from Promega (Madison, WI), and rhTWEAK was
obtained from PeproTech (Rocky Hill, NJ). GM6001
Cherry et al. Molecular Cancer  (2015) 14:9 Page 11 of 13inhibitor and MMP Inhibitor I were obtained from EMD
Millipore (Temecula, CA).3-D invasion assays
Invasion assays were performed as described previously
[17,18]. In brief, Type I collagen extracted from rat tail
tendons [32] was diluted to 2 mg/ml in DMEM/F12
(1× Pen/Strep) and matrices polymerized in 96-well plates.
40,000 cells per well were seeded in 100 μl DMEM/F12
(1× Pen/Strep, 1× Glutamax) without growth factors or
serum. Cells were fixed with 3% glutaraldehyde solution
after 48 h of invasion and stained with 0.1% toluidine blue.
Invasion density was quantified by counting cells below the
plane of the monolayer by bright-field light microscopy
using a 10 × 10 ocular grid at 10× magnification corre-
sponding to a 1 mm2 field. Numbers in equivalent fields
were counted (n = 3 wells). Cross-sectional images were
taken with an Olympus CKX41 inverted microscope and
Q-Color 3 camera.Western blots
Whole-cell lysates were prepared using RIPA buffer with
1X Halt protease and phosphatase inhibitors (Thermo
Scientific, Rockford, IL). Cytoplasmic and nuclear ex-
tracts were prepared as previously described [33].
25-40 μg of protein was separated in replicate 9% poly-
acrylamide (29:1 Bis) Tris gels and transferred to repli-
cate nitrocellulose membranes for probing proteins in
parallel. After transfer, gels were stained with GelCode
Coomassie (Thermo Scientific, Rockford, IL) and
scanned with the IR700 channel of an Odyssey Infrared
Imaging system (LI-COR Biosciences, Lincoln, NE) for
first verification of even protein loading. Westerns
were performed by blocking membranes in 1:1 PBS/
Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln,
NE) prior to co-incubation with mouse and rabbit primary
antibodies. Simultaneous detection was performed using
goat anti-rabbit IRDye800CW and goat anti-mouse
IRDye680 secondary antibodies (LI-COR Biosciences,
Lincoln NE). Membranes were probed in parallel for
simultaneous detection of multiple antibodies in repli-
cate membranes without stripping. Western blots and
Coomassie-stained gels were scanned with the Odyssey
Imager. Color images were scanned with a LI-COR
Infrared Imaging System, converted to black and white,
and analyzed using the LI-COR Image Studio software.
Quantitative analysis of indicated images was performed
using Image Studio or Image J software (NIH, Bethesda,
MA). The following Santa Cruz Biotechnology (SC, Santa
Cruz, CA) and Cell-Signaling Technology (CST, Dan-
vers, MA) antibodies were used: RelB (CST-4922), RelA
(SC- 8008), Phospho-RelA Ser536 (CST-3033), c-Rel
(CST-4727), p100/p52 (CST-3017), p105/p50 (CST 13681),LaminA (SC 56137), IkBα (CST 4814), NIK (CST 4994),
β-Actin (SC-69879).
Plasmids
pLenti6 overexpression constructs for RelB and NIK
were generated by subcloning cDNA into pLenti6-V5-
DEST (Addgene, Cambridge, MA) using the GATE-
WAY™ Cloning System. Luciferase (Promega, Madison,
WI) or tagRFP (Evrogen, Moscow, Russia) coding se-
quences were subcloned into pLeni6-V5-DEST and used
as controls for RelB and NIK overexpression. Mission™
Lentiviral shRNA plasmids for RelA, RelB and control
were purchased from Sigma-Aldrich (St. Louis, MO).
shRelB, as well as its control, was described previously
as shRelB-3 [17]. shNFKB2 and shControl oligonucleo-
tides (Integrated DNA Technologies, Coralville, IA) were
subcloned into pLKO.1-puro (Addgene, Cambridge,
MA). Exact sequences are available upon request.
Lentivirus production and transduction
293T cells were transfected with 7 μg of lentiviral plas-
mids using 21 μg of polyethyleneimine (Polysciences
Inc., Warrington, PA). Lentiviruses were harvested after
3 days and used to infect 2x105 glioma cells. Transduced
cells were selected for 72 h in DMEM/F12 NSC medium
containing 0.6 μg/ml Puromycin or 3 μg/ml Blasticidin
(Invivogen, San Diego, CA) to verify stable transduction.
Cells were continuously selected during culture with
0.6 μg/ml Puromycin (shRNA constructs) and/or 6 μg/ml
Blasticidin (overexpression constructs).
Quantitative reverse-transcriptase PCR
Total RNAs were isolated from cells using Purelink™
RNA Mini Kit (Life Technologies, Carlsbad, CA). cDNA
was synthesized from 1 μg of total RNA using Super-
Script® III Reverse Transcriptase (Life Technologies,
Carlsbad, CA) following manufacturer’s instructions.
Quantitative RT-PCR was performed using SYBR® Green
PCR Master Mix (Applied Biosystems, Foster City CA).
Expression of mRNA was normalized to either GAPDH
or RPLP0 expression levels. The following primers were
used in amplifications: GAPDH 5′-AATGAAGGGGTC
ATTGATGG-3′, 5′-AAGGTGAAGGTCGGAGTCAA-3′;
RPLP0 5′- TCGTCTTTAAACCCCTGCGTG-3′, 5′-TG
TCTGCTCCCACAATGAAAC-3′; MMP-2 5′-AAGAAG
TAGCTGTGACCGCC-3′ 5′-TTGCTGGAGACAAATT
CTGG-3′; MMP9 5′-GCACTGCAGGATGTCATAGG-3′
5′-ACGACGTCTTCCAGTACCGA-3′; MMP-14 5′-TGC
CTACCGACAAGATTGATG-3′ 5′-ATCCCTTCCCAGA
CTTTGATG-3′; NIK 5′-TTCAGCCCCACCTTTTCAG-
3′ 5′-ACGCTTTCCCTTCCAACAC-3′. All experiments
were performed at least three times with three replicates
per sample.
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All animal experiments were done in compliance with
IACUC, AAALAC and Texas A&M University Health
Science Center Biosafety guidelines using an IACUC-
approved Animal Use Protocol (# 2012–174). For orthoto-
pic tumor inoculations, cells were labeled using a DiD
(DiIC18(5); 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindodi-
carbocyanine, 4-chlorobenzenesulfonate salt) cytoplasmic
membrane dye; abs/em = 644/655 (Biotium, Hayward,
CA) according to the manufacturers directions. 0.5-1×106
cells in 3–5 μl phosphate buffered saline were injected into
the right cortex of 4–6 week old CD-1 nude mice (n = 3
each). Tumor cells were imaged in vivo at indicated times
post-injection using an IVIS Spectrum In Vivo Imaging
System and Living Image Software (Perkin Elmer, Waltham,
MA). Tumor volume was calculated from the formula:
Volume = 0.5 × length × width2. The highest and lowest
numbers for calculated tumor volume in each group
were excluded from analysis.Statistical analyses
GraphPad Prism 5 software was used for all statistical
analyses. Paired student’s t-test or one-way analysis of
variance (ANOVA) with Tukey’s honest significant dif-
ference (H.S.D.) post-test was performed and an α-value
of 0.05 was used as criteria for statistical significance.Additional file
Additional file 1: Figure S1. Efficiency of RelA knockdown among
multiple shRNA constructs and quantification of RelB overexpression. Figure S2.
TWEAK specifically induces noncanonical NF-κB activation in glioma cells via
NIK protein accumulation. Figure S3. TWEAK-enhanced invasion is attenuated
by broadspectrum MMP and MMP9-selective inhibition. Figure S4. NIK
overexpression specifically induces p100 processing in glioma cells.
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